Related Experiment Video
Updated: Jul 23, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia
Heidy M Roncancio1, Julián R Lugo-Peña2, Ángel A García3
1Cardiocolombia, Colombia.
Insights
Evolocumab significantly reduced LDL cholesterol in hyperlipidemia patients, with a 63.9% drop in 3 months. Treatment showed good persistence and safety, making it effective for managing high cholesterol.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Cardiovascular disease (CVD) is a leading global cause of death, with elevated cholesterol as a major risk factor.
- Hyperlipidemia management is crucial for CVD prevention.
- Evolocumab offers a therapeutic option for patients with hyperlipidemia.
Purpose of the Study:
- To describe the clinical characteristics of patients with hyperlipidemia treated with evolocumab.
- To evaluate treatment patterns and effectiveness of evolocumab in a real-world setting.
- To assess the safety and persistence of evolocumab therapy.
Main Methods:
- Observational study utilizing chart review of hyperlipidemia patients in Colombia.
- Inclusion of patients receiving evolocumab as part of clinical management.
- Analysis of lipid levels, treatment persistence, and adverse events.
Main Results:
- Evolocumab treatment led to a 63.9% reduction in LDL-C within 3 months (median 147 to 53 mg/dL).
- Sustained LDL-C reduction below 45 mg/dL throughout follow-up.
- High treatment persistence (72%) and low incidence of adverse events (5.2%) reported.
Conclusions:
- Evolocumab effectively reduces LDL-C levels in patients with hyperlipidemia.
- The medication demonstrates favorable persistence and a good safety profile.
- Evolocumab is a viable treatment option for managing hyperlipidemia and reducing cardiovascular risk.
Background:
Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one of the leading risk factors for CVD. We describe the clinical characteristics, treatment patterns, and effectiveness of evolocumab in treating hyperlipidemia.
Methods:
Observational study conducted through a chart review of patients with hyperlipidemia receiving evolocumab as part of clinical management in Colombia.
Results:
This study included 115 patients treated with evolocumab. A total of 101 patients (87.8%) had a history of CVD, 13 (11.3%) familial hypercholesterolemia (FH), and 23 (20%) type 2 diabetes. Thirty-nine patients reported intolerance to any statin (33.9%). The median value of LDL-C before initiation of evolocumab was 147mg/dL (IQR: 122.5-183.7mg/dL). Within the first 3 months of treatment, LDL-C value dropped to a median value of 53mg/dL (IQR: 34.0-95.5mg/dL), showing a reduction of 63.9%. The median LDL-C values remained below 45mg/dL until the end of follow-up. Among the patients with available data, up to 61% achieved an LDL-C level below 55mg/dL at the 10-12-month follow-up. A total of 72% of patients were persistent with treatment. Safety results showed a low frequency of hospitalizations (≤2%) and treatment-emergent adverse drug reactions (5.2%). No serious adverse events were reported.
Conclusions:
Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:30Acute Coronary Syndrome III: Diagnostic Studies